摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,3-二氨基-6,8-二甲基-1,5-二苯基-2,4,6,8-四氮杂双环[3.3.0]辛-3-烯-7-酮 | 6093-74-9

中文名称
2,3-二氨基-6,8-二甲基-1,5-二苯基-2,4,6,8-四氮杂双环[3.3.0]辛-3-烯-7-酮
中文别名
——
英文名称
7-propoxycoumarin-3-carboxylic acid
英文别名
2-oxo-7-propoxy-2H-chromene-3-carboxylic acid;3-carboxy-7-propoxycoumarin;2-Oxo-7-propoxy-2H-chromen-3-carbonsaeure;2-oxo-7-propoxychromene-3-carboxylic acid
2,3-二氨基-6,8-二甲基-1,5-二苯基-2,4,6,8-四氮杂双环[3.3.0]辛-3-烯-7-酮化学式
CAS
6093-74-9
化学式
C13H12O5
mdl
——
分子量
248.235
InChiKey
SSTDMTGGXAZVTI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    199-200 °C
  • 沸点:
    436.6±45.0 °C(Predicted)
  • 密度:
    1.346±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    72.8
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2932209090

SDS

SDS:d18532d4acb44546c3654222134baeb1
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities
    作者:Jiaoli Ding、Jing Liu、Zhipeng Zhang、Jie Guo、Maojun Cheng、Yang Wan、Rikang Wang、Yuanying Fang、Zhiyu Guan、Yi Jin、Sai-Sai Xie
    DOI:10.1016/j.bioorg.2020.104023
    日期:2020.8
    A series of novel coumarin-based N-hydroxycinnamamide derivatives were designed and synthesized as histone deacetylase (HDAC) inhibitors. Most of the synthesized compounds showed potent HDAC inhibitory activity and significant antiproliferative activity against human cancer cell lines MCF-7, HepG2, HeLa and HCT-116. Among them, compound 14f displayed the most potent HDAC inhibition, especially against
    设计并合成了一系列基于香豆素的新型N-羟基肉桂酰胺衍生物,作为组蛋白脱乙酰基酶(HDAC)抑制剂。大多数合成的化合物对人癌细胞系MCF-7,HepG2,HeLa和HCT-116均显示出有效的HDAC抑制活性和显着的抗增殖活性。其中,化合物14f表现出最有效的HDAC抑制作用,尤其是对HDAC1的IC 50值为0.19μM,优于SAHA(IC 50  = 0.23μM)。与HDAC6相比,它还显示出对HeLa细胞最强的抗增殖活性,对HDAC1的选择性超过26倍。分子对接研究揭示了化合物14f的可能结合方式分为两个同工型,并为选择性提供了合理的解释。此外,化合物14f可以抑制菌落形成,上调组蛋白H3的乙酰化水平,并诱导HeLa细胞中G2 / M期的凋亡和细胞周期停滞。综上所述,这些结果强调了化合物14f可能是一种有前途的HDAC癌症治疗抑制剂。
  • 具潜在抗AD活性的香豆素杂合吡啶酮酰胺衍 生物及其制备方法与应用
    申请人:浙江工业大学
    公开号:CN110804045B
    公开(公告)日:2021-07-27
    本发明公开了一种香豆素杂合吡啶酮酰胺衍生物及其制备方法与应用。所述的香豆素杂合吡啶酮酰胺衍生物及其药学上可接受的盐如式(I)或式(II)所示,其可应用于制备抗阿尔兹海默症、抗帕金森病或通过抑制单胺氧化酶、螯合金属铁离子、抗Aβ及抗氧化来治疗的其它疾病或病症药物方面的用途。
  • Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents
    作者:Tooba Abdizadeh、Mohammad Reza Kalani、Khalil Abnous、Zahra Tayarani-Najaran、Bibi Zahra Khashyarmanesh、Rahman Abdizadeh、Razieh Ghodsi、Farzin Hadizadeh
    DOI:10.1016/j.ejmech.2017.03.024
    日期:2017.5
    synthesized as HDAC inhibitors. The cytotoxic activity of the synthesized compounds (8a-u) was evaluated against six human cancer cell lines including HCT116, A2780, MCF7, PC3, HL60 and A549 and a single normal cell line (Huvec). We evaluated their inhibitory activities against pan HDAC and HDAC1 isoform. Four compounds (8f, 8q, 8r and 8u) showed significant cytotoxicity with IC50 in the range of 0.53-57
    组蛋白脱乙酰基酶(HDAC)是治疗癌症和其他疾病的有吸引力的治疗靶标。它具有四类(I-IV),其中特别是I类同工酶与促进肿瘤细胞的增殖,血管生成,分化,侵袭和转移有关,并且也是癌症治疗的可行靶标。设计并合成了一系列新的基于香豆素的苯甲酰胺作为HDAC抑制剂。评估了合成的化合物(8a-u)对六种人类癌细胞系的细胞毒活性,包括HCT116,A2780,MCF7,PC3,HL60和A549,以及一种正常细胞系(Huvec)。我们评估了它们对泛HDAC和HDAC1亚型的抑制活性。四种化合物(8f,8q,8r和8u)显示出明显的细胞毒性,IC50在0.53-57范围内。47±0.02μM几乎等于参比药物恩替司他(IC50 = 0.41±0.06μM)。化合物8a的分子对接研究和分子动力学模拟显示了该化合物与HDAC1酶之间可能的相互作用方式。47±0.02μM几乎等于参比药物恩替司他(IC50 = 0
  • Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity
    作者:Xiaoying Jiang、Jianan Guo、Yangjing Lv、Chuansheng Yao、Changjun Zhang、Zhisheng Mi、Yuan Shi、Jinping Gu、Tao Zhou、Renren Bai、Yuanyuan Xie
    DOI:10.1016/j.bmc.2020.115550
    日期:2020.6
    A series of (3-hydroxypyridin-4-one)-coumarin hybrids were developed and investigated as potential multi targeting candidates for the treatment of Alzheimer's disease (AD) through the incorporation of iron-chelating and monoamine oxidase B (MAO-B) inhibition. This combination endowed the hybrids with good capacity to inhibit MAO-B as well as excellent iron-chelating effects. The pFe(3+) values of the compounds were ranging from 16.91 to 20.16, comparable to more potent than the reference drug deferiprone (DFP). Among them, compound 18d exhibited the most promising activity against MAO-B, with an IC50 value of 87.9 nM. Moreover, compound 18d exerted favorable antioxidant activity, significantly reversed the amyloid-beta(1-42) (A beta(1-42)) induced PC12 cell damage. More importantly, 18d remarkably ameliorated the cognitive dysfunction in a scopolamine-induced mice AD model. In brief, a series of hybrids with potential anti-AD effect were successfully obtained, indicating that the design of iron chelators with MAO-B inhibitory and antioxidant activities is an attractive strategy against AD progression.
  • Thaker, N. N.; Trivedi, K. N., Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical and Analytical, 1981, vol. 20, # 6, p. 560 - 563
    作者:Thaker, N. N.、Trivedi, K. N.
    DOI:——
    日期:——
查看更多